Fairchem Organics Ltd
Fairchem Organics Q3 FY25 earnings call: Revenue & Margins
Q3 FY25 earnings call: what management guided on revenue, margins and order book.
The short version
Management anticipates revenue to substantially grow with the commercialization of new high-value products, including isostearic acid and another new product with 40,000 MT capacity that could potentially double current sales. Isostearic acid, a high-value, value-added product, is expected to significantly boost margins and revenues starting from April 2025.
From Fairchem Organics Ltd's Q3 FY25 earnings-call transcript · updated 23 Aug 2026.
Revenue & Sales Performance
- Management anticipates revenue to substantially grow with the commercialization of new high-value products, including isostearic acid and another new product with 40,000 MT capacity that could potentially double current sales.
- Isostearic acid is expected to ramp up gradually, with approvals and marketing ongoing; full capacity utilization and significant export volumes projected within 2-3 years.
- The new product commercialization is targeted within FY26, with plant installation completed and production costs/yields being optimized.
- Market entry for these products will be gradual due to high product quality standards and long approval cycles, especially for export markets in cosmetics, pharmaceuticals, and biodegradable lubricants.
- Domestic and export demand for isostearic acid is growing, with exports constituting nearly 90-100% of sales.
2 more points from Fairchem Organics Ltd's call on revenue
Pro opens every point from 15K+ earnings calls
Profitability & Margins
See what Fairchem Organics Ltd said on profitability & margins — free account, 30 seconds.
Capital Expenditure Plans
- The company has completed designing and obtained all permissions for new equipment.
- Financial resources are available and include zero long-term debt; working capital and potential borrowing capacity up to Rs. 250 crores are accessible.
- The next step is to place orders for the new equipment once manufacturing cost and yields are confidently optimized.
- Plant setup timeline is estimated at 1 to 1.5 to 2 years.
- After plant commissioning, it will take around 1.5 years for the product to complete the approval cycle.
- Full capacity operations are expected within approximately three years after the final decision to proceed.
2 more points from Fairchem Organics Ltd's call on capex
Pro opens every point from 15K+ earnings calls
Top-ranked in Chemicals & Petrochemicals
Ranked on what management guided this quarter
Rank buckets describe management commentary on revenue and margin. Not investment advice, and not a forecast of returns.
Fundraising & Capital Structure
See what Fairchem Organics Ltd said on fundraising & capital structure — free account, 30 seconds.
Order Book & Pipeline
- The company has completed designing and obtained all necessary permissions for the new project.
- Funding is in place; money is available for project execution.
- The order placement for equipment is pending until the company is confident about manufacturing costs and yields.
- Once confident, project implementation will take approximately 1 to 1.5-2 years.
2 more points from Fairchem Organics Ltd's call on order book
Pro opens every point from 15K+ earnings calls
Fairchem Organics Ltd — Quarterly revenue & net profit
Reported quarterly figures (₹ Cr). Latest (Q4 FY26): revenue ₹117 Cr, net profit ₹4 Cr. Revenue and profit are scaled separately — hover a quarter for exact figures.
Full financials →Continue your research
What Fairchem Organic's management said in earlier quarters
- Q1 FY27 earnings call analysis →
- Q4 FY26 earnings call analysis →
- Q3 FY26 earnings call analysis →
- Q2 FY26 earnings call analysis →
- Q1 FY26 earnings call →
- Q4 FY25 earnings call →
- Q2 FY25 earnings call →
- Q1 FY25 earnings call →
- Q4 FY24 earnings call →
- Q3 FY24 earnings call →
- Q2 FY24 earnings call →
- Q1 FY24 earnings call →
Others in Chemicals & Petrochemicals this season
- Himadri Special (Q3 FY25)
1,131.81 Crs, up 7.53% YoY (from Rs. Key concall takeaways from Himadri Speciality Chemical Ltd's Q3 FY25 earnings call — and how it ranks against sector peers.
- Gujarat Alkalies (Q3 FY25)
3,702.77 Crores (up from Rs. Key concall takeaways from Gujarat Alkalies & Chemicals Ltd's Q3 FY25 earnings call — and how it ranks against sector peers.
- Balaji Amines (Q3 FY25)
Q3FY25 consolidated revenue from operations was ₹321 crore, down 18% YoY from ₹392 crore in Q3FY24 (Page 7). Key concall takeaways from Balaji Amines Ltd's Q3…
- Vidhi Specialty (Q3 FY25)
Year-on-Year (Y-o-Y) Growth:** 56.5% increase . Key concall takeaways from Vidhi Specialty Food Ingredients Ltd's Q3 FY25 earnings call — and how it ranks…
Arthneeti Pro · Annual
Fairchem Organics Ltd and 15K+ more earnings calls,
for less than your morning chai
a day
Every earnings call, ranking and concall Q&A across all four results seasons.
Secure Razorpay payment · instant access
Frequently Asked Questions
What were Fairchem Organics Ltd Q3 FY25 results?
Management anticipates revenue to substantially grow with the commercialization of new high-value products, including isostearic acid and another new product with 40,000 MT capacity that could potentially double current sales. Isostearic acid, a high-value, value-added product, is expected to significantly boost margins and revenues starting from April 2025.
What is Fairchem Organics Ltd share price analysis?
Fairchem Organics Ltd currently shows a neutral. The stock trades at a P/E of 66.5 with a market cap of ₹1,005 Cr. Investors should review the full earnings analysis for detailed insights.
Is Fairchem Organics Ltd planning capital expenditure?
The company has completed designing and obtained all permissions for new equipment. - Financial resources are available and include zero long-term debt; working capital and potential borrowing capacity up to Rs.
Keep Fairchem Organics Ltd on your radar — track it to get its next earnings analysis in your feed.
This analysis is AI-generated based on publicly available earnings data and the company's earnings call transcript. This is not investment advice. Please consult a SEBI-registered advisor before making investment decisions.